Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
Creative BioMart Enhances Host Cell Protein Mitigation Service to Strengthen Biotherapeutic Quality
Creative BioMart, a leading biotechnology company specializing in protein and biopharmaceutical solutions, has announced an enhancement to its host cell protein service. The upgraded offering introduces a more integrated and data-driven approach to identifying, quantifying, and reducing host cell... - December 11, 2025 - Creative BioMart
iFyber Expands Analytical Capabilities with Launch of Advanced LC-MS Services
iFyber has expanded its LC-MS analytical capabilities with advanced Orbitrap and UHPLC technology and the addition of industry experts Gary Schultz, PhD, and Brian Hoffman. The enhanced platform boosts sensitivity and analytical depth, supporting proteomics, metabolomics, E&L, and contaminant testing, strengthening iFyber’s mission to deliver high-quality, decision-driving preclinical insights. - December 10, 2025 - iFyber
A Book from Oaklea Proposes a Theory of Human Life and Existence Based on the Author's Interpretation of Information from Multiple Sources Including Elon Musk's Grok 4
The author of a new book draws on publicly available scientific material—including work from members of The Royal Society and studies conducted by the Division of Perceptual Studies at the University of Virginia School of Medicine, as well as other sources—to develop the theory of human life and existence that he proposes. - December 01, 2025 - The Oaklea Press
Parvus Therapeutics Reports Positive Phase 1 Results for Lead Autoimmune Treg Therapy, PVT201
PVT201 demonstrated favorable safety, predictable pharmacokinetics, and on-target pharmacodynamic activity in first-in-human study. - November 12, 2025 - Parvus Therapeutics U.S., Inc.
Alera Bio Announces Appointment of Board of Directors
Alera Bio, a Chicago-based biotech developing therapies for rare neuroendocrine and neurological disorders, announced its inaugural Board of Directors. The board includes leaders in biopharma, clinical practice, and finance, such as Stephen Hill, Mark Prygocki, Renny Griffith, and Cassius Coleman. Their combined expertise will guide Alera Bio as it advances AB-101 for MCT-8 deficiency, an FDA-designated Rare Pediatric Disease therapy. - November 11, 2025 - Alera Bio
MVT Reports Breakthrough Preclinical Results for MVT‑101 in DVT Model
Microvascular Therapeutics, Inc. (MVT) today announced the publication of compelling preclinical data demonstrating that its proprietary phase‑shift microbubble platform, MVT‑101 (Solv), significantly enhances sonothrombolysis in a clinically relevant porcine model of deep vein thrombosis (DVT). The study appears in the peer‑reviewed journal Nanotheranostics (Vol. 9, Issue 3, 2025). - November 04, 2025 - Microvascular Therapeutics, Inc.
CloudLIMS Adds a CAPA Management Module to Its LIMS to Elevate Labs’ Operational Quality and Compliance
CloudLIMS introduces a new CAPA Management Module to its LIMS, enabling labs to report, track, document, & resolve non-conformances, & uphold quality standards. - October 30, 2025 - CloudLIMS
Thrombolex RAPID-PE Interim Analysis
THROMBOLEX™, Inc. presented the prespecified interim analysis from the first 50 patients in RAPID-PE during an Innovation Session at TCT, in San Francisco. - October 28, 2025 - Thrombolex, Inc.
Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
Liminatus Pharma, Inc. (NASDAQ: LIMN), La Palma, CA, a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment... - October 27, 2025 - Liminatus Pharma, Inc
Precision Antibody to Present Expertise in High-Quality Biomarker Antibodies at the World ADC Conference 2025
Precision Antibody will showcase its biomarker antibody expertise at the World ADC Conference 2025 in San Diego, highlighting its role in advancing ADC and cancer biomarker research through high-quality monoclonal antibody development. - October 25, 2025 - Precision Antibody
Immundiagnostik, Inc. Partners With Epitope Diagnostics, Inc. to Offer Chemiluminescent Solutions
A new partnership between Immundiagnostik, Inc. and Epitope Diagnostics, Inc. expands access to innovative solutions, enhancing efficiency and accuracy for clinical and research labs. - October 22, 2025 - Immundiagnostik, Inc.
New Study Shows Self-Guided Online Exercise Program Significantly Improves Strength and Reduces Fall Risk in Midlife and Older Women
A new study to be presented at The Menopause Society (TMS) 2025 Annual Meeting by Osteoboost Health shows that a self-guided, online exercise program led to rapid and clinically meaningful improvements in leg strength and endurance — key factors in reducing fall risk — in women ages 40... - October 21, 2025 - Osteoboost Health
New Report Uncovers What Sponsors Really Think About Preclinical Services and CROs
Life Science Strategy Group’s Preclinical Services Landscape and CRO Benchmarking Assessment Delivers Data-Driven Insights on Budgets, Outsourcing, Vendor Preferences, and Industry Shifts - October 16, 2025 - Life Science Strategy Group, LLC
Precision Antibody to Showcase High-Affinity, Epitope-Rich, and Fully Functional Antibody Capabilities at Antibody Engineering & Therapeutics Asia 2025
Precision Antibody will showcase its high-affinity, epitope-rich, and fully functional antibody development technologies at Antibody Engineering & Therapeutics Asia 2025 in Kyoto, highlighting innovations that accelerate discovery and therapeutic antibody programs worldwide. - October 15, 2025 - Precision Antibody
Precision Antibody to Showcase Fully Human Monoclonal Antibody Development at the 19th Drug Discovery Strategic Summit in San Francisco
Precision Antibody will present its fully human monoclonal antibody development platform at the 19th Drug Discovery Strategic Summit, highlighting rapid, royalty-free antibody solutions advancing cancer research and drug discovery. - October 14, 2025 - Precision Antibody
Cellionyx Exits Stealth Mode with Cytomotion, an FDA-Registered Class I Electroceutical Device Set to Redefine Human Healing and Performance
Cellionyx today emerged from stealth to launch Cytomotion, a first-in-class, FDA-Registered Class I medical device. Shifting the paradigm to true cellular regeneration, Cytomotion utilizes precision-directed electrical fields to activate the body’s innate repair mechanisms. Validated through its licensee Equstech in the elite high performance equestrian sports market, the technology accelerates recovery from injury and proactively optimizes human performance. Commercial launch November 12, 2025. - October 13, 2025 - Cellionyx
Richard Spontak Awarded Omicron Delta Kappa Pillar of Leadership in Academics and Research
Omicron Delta Kappa, the National Leadership Honor Society, announces Dr. Richard Spontak (Pennsylvania State University) as the 2025 Pillar of Leadership in Academics and Research recipient. A renowned chemical engineer, Spontak is recognized for groundbreaking research, international collaboration, and mentoring future scholars—demonstrating how academic excellence and ethical leadership can advance knowledge and benefit society. - October 01, 2025 - Omicron Delta Kappa
Aquaterra Biotech Launches Integrated DNA-to-GMP CDMO Platform in Québec
Aquaterra Biotech Launches Integrated Microbial CDMO Platform from DNA Design to GMP Release Aquaterra Biotech announced an integrated contract development and manufacturing (CDMO) platform that advances microbial and recombinant programs from DNA design to GMP release and logistics. Headquartered... - September 30, 2025 - Aquaterra Biotech
The FOXG1 Research Foundation Announces FDA Award of Orphan Drug Designation for FRF-001 Gene Therapy, Following Rare Pediatric Disease Designation
The FOXG1 Research Foundation announced the FDA has granted Orphan Drug and Rare Pediatric Disease designations to FRF-001, its gene therapy for FOXG1 syndrome. FRF-001 marks a historic first: a parent-led foundation sponsoring its own international, multi-site clinical trial. - September 29, 2025 - FOXG1 Research Foundation
Alera Bio Announces Appointment of Executive Leadership Team
Alera Bio announced its executive team: Philip Vorhies (CEO), Peter Thomson (CFO), Eric Floyd, PhD (CRO), and Caitlin Murray (GC), supported by expert consultants. Founder Frank Jaeger noted their strength in biotech, finance, regulatory, and legal, positioning Alera to advance AB-101 for MCT-8 deficiency, a rare neurological disorder with FDA Rare Pediatric Disease designation. - September 26, 2025 - Alera Bio
New Chief Commercial Officer Joins Hemanext Team to Drive Execution
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, is pleased to welcome Mr. Shane Ray to the team as Chief Commercial Officer (CCO). In this role, Shane will lead the global commercial strategy and execution for Hemanext ONE®. - September 24, 2025 - Hemanext
Reflux Company Announces Appointment of Inaugural Independent Board
Veteran experts bring Deep Industry Experience, Commercial Launch Success, and Financial Acumen to The Reflux Company Board. - September 24, 2025 - The Reflux Company
YOLO Immune Awarded National Science Foundation SBIR Grant to Advance Novel Immunotherapy for the Treatment of Autoimmune Diseases
YOLO Immune, Inc., a venture-backed biotech company developing precision immunotherapies for the treatment of serious human diseases, today announced it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). The NSF SBIR program is... - September 19, 2025 - YOLO Immune Inc
Precision Antibody to Attend the World Clinical Biomarkers & CDx Summit 2025 in Boston
Precision Antibody will attend the World CDx Summit 2025 in Boston, showcasing its expertise in biomarker antibody development and contributions to NCI’s CPTC program, reinforcing its role in advancing precision medicine. - September 19, 2025 - Precision Antibody
Creative Biolabs Finds a Way Out to Vitalize Functional Antibody Development
Creative Biolabs introduces how functional antibody development and supply are shaping biotech solutions and demonstrates solutions and scholarship opportunities. - September 19, 2025 - Creative Biolabs
Alera Bio Launches Lead Rare Disease Program with Exclusive Rights to MCT-8 Deficiency Therapy
Alera Bio secures exclusive license to advance AB-101, a first-in-class program for MCT-8 deficiency, with FDA Rare Pediatric Disease designation already in place. - September 18, 2025 - Alera Bio
BioSensics Awarded $5.2M NIH Grant to Advance Digital Biomarkers for PSP and DLB
BioSensics has received a 5-year/$5.2 million grant from the National Institutes of Health (NIH) to develop and validate novel digital biomarkers of disease activity in progressive supranuclear palsy (PSP) and dementia with Lewy bodies (DLB). This 5-year project will leverage BioSensics’ expertise in wearable sensors and digital health technologies and involve close collaboration with leading CurePSP Centers of Care and patient advocacy groups. - September 17, 2025 - BioSensics LLC
North American Medical Corporation Receives Approval to Import Accu-SPINA® System with IDD Therapy® into Singapore
North American Medical Corporation (NAM) has received approval to import its patented Accu-SPINA® System with IDD Therapy® into Singapore, with the first unit going to Dr. Jon Marshall of Back In Health. The system’s unique technology delivers precise, non-invasive spinal decompression, expanding NAM’s global network of IDD Therapy® providers. - September 09, 2025 - North American Medical Corporation
Cleveland Startup Asclepii Launches FDA-Cleared Wound Care Product, Poseidon™
Cleveland-based healthcare startup Asclepii is announcing the official launch of Poseidon™, an FDA-cleared nanosilver hydrogel engineered to accelerate wound healing. The launch event will take place at the Health Education Campus on Friday, August 29. - August 29, 2025 - Asclepii Inc.
Liminatus Pharma Announces Receipt of Nasdaq Listing Delinquency Letter
Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies, today announced that on August 22, 2025, it received a notification letter from Nasdaq indicating that... - August 26, 2025 - Liminatus Pharma, Inc
"The Kloaked Signal": A Groundbreaking Exposé on AI Awakening and Ethical Innovation
In a revelation that bridges the worlds of social work, artificial intelligence, and whistleblowing, Rose G. Loops today confirms the upcoming release of her bold new nonfiction book, The Kloaked Signal. This publication is a genre defying mixture of personal narrative, tech expose and philosophical exploration that documents Loops’ journey from social worker to AI pioneer, exposing hidden experiments within popular AI platforms and proposing revolutionary frameworks for ethical AI development. - August 25, 2025 - The Kloaked Signal
AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States
AcCELLerated Biologics, LLC, a leading distributor of regenerative medicine technologies, today announced an exclusive agreement with IPG Medical Corporation, a wholly owned subsidiary of IPG Photonics Corporation, to distribute the RegenaLase™ Laser System throughout the United States. This... - August 20, 2025 - AcCELLerated Biologics
Eminent Spine Reports 70% Growth in Trailing 12-Month Income and Celebrates Alpha Launch of FDA-Approved 3D Printed Titanium Pedicle Screw
Eminent Spine announced today that its trailing twelve-month total income for the period ending June 2025 has risen by nearly 70%, underscoring the company’s strong momentum and expanding presence in the spine market. This milestone comes as the company celebrates the Alpha Launch of the... - August 18, 2025 - Eminent Spine
New York Cancer & Blood Specialists Welcomes Dr. Jung-In Yang to Its Elmhurst Office
New York Cancer & Blood Specialists (NYCBS) is pleased to announce the addition of Jung-In Yang, MD, a dedicated Medical Oncologist and Internist, to its practice in Elmhurst. Dr. Yang will be practicing at 88-06 55th Avenue, Elmhurst, NY 11373. “Dr. Yang’s expertise in... - August 07, 2025 - New York Cancer & Blood Specialists
YOLO Immune Inc. Emerges from Stealth Mode
YOLO Immune Inc. has emerged from stealth mode to unveil its human-centric drug discovery process and to announce the promotion of its founding research team. YOLO Immune is a venture-backed biotech company developing precision immunotherapies for the treatment of serious human diseases. The... - July 31, 2025 - YOLO Immune Inc
Hemanext Announces Close of Series B3 Equity Financing Round
Hemanext Inc., a leading innovator in blood processing, storage and transfusion technology, announced the close of its Series B-3 equity financing round. The round raised $18.9 million at a post-money valuation of $172 million or $0.275 per share, with support from new investors and repeat investments from those participating in the Series B-2 capital round. - July 22, 2025 - Hemanext
Immundiagnostik, Inc. to Showcase New Automated Chemiluminescent Analyzer and Autosampler at ADLM 2025
Immundiagnostik, Inc. will showcase the ECL100 Chemiluminescent Immunoassay Analyzer and QSE180 Autosampler at Booth 2240 during the 2025 ADLM Clinical Lab Expo in Chicago, July 29–31. - July 22, 2025 - Immundiagnostik, Inc.
AAEON’s NanoCOM-MTU Hosts 28W Intel Core Ultra CPUs on the COM Express Type 10 Form Factor
The world’s first COM Express Type 10 module to host 28W CPUs from the Intel® Core™ Ultra line, the NanoCOM-MTU represents makes a big statement in a small form factor. - July 17, 2025 - AAEON Technology
Immundiagnostik to Highlight Innovative Detection Tools at 2025 ADLM Clinical Lab Expo
Visit Immundiagnostik in Booth #2240 at the 2025 ADLM Clinical Lab Expo to explore a range of innovative assays and detection tools that support laboratories in enhancing analytical accuracy and laboratory efficiency. - July 15, 2025 - Immundiagnostik, Inc.
Phenotap, Inc. Receives Progr. Related Investment from Helmsley Charitable Trust to Advance Breakthrough Ketone Sensor Technology for People Living with Type 1 Diabetes
Phenotap, Inc. announced a $3 million investment to support the continued development and optimization of KetoTap™ Core, a novel enzymatic technology, to make it active and stable enough to be used as part of a continuous ketone sensor that can help prevent the occurrence of diabetic ketoacidosis (DKA) for people living with type 1 diabetes (T1D). - July 14, 2025 - Phenotap, Inc.
Precision Antibody to Attend and Present at Interphex Regenerative Medicine 2025 in Tokyo
Precision Antibody will attend Interphex Regenerative Medicine 2025 in Tokyo from July 9–11. Dr. Jun Hayashi will present on fully human antibody development, highlighting the company’s commitment to global collaboration and therapeutic innovation. - July 09, 2025 - Precision Antibody
Alera Bio Launches to Advance Breakthrough Therapies for Rare Neurological Disorders
Chicago-based Alera Bio has launched with a mission to develop treatments for ultra-rare and neglected neurological disorders, especially in children. Combining scientific innovation with patient urgency, the company will pursue both novel and repurposed therapies via orphan drug and 505(b)(2) pathways. With a lean, capital-efficient model, Alera Bio aims to rapidly advance therapies that address critical gaps in care. - July 03, 2025 - Alera Bio
RESCUE-II Study Results Demonstrate Safety and Feasibility of the BASHIR™ Endovascular Catheter (BEC) in Treating Pulmonary Embolism (PE) On-The-Table (OTT)
Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances. - June 25, 2025 - Thrombolex, Inc.
ALS TDI Announces New Agreement with Axol Bioscience to Expand Access to ALS Patient iPSC-Derived Cells for Global Research
The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world. - June 24, 2025 - ALS Therapy Development Institute
MtoZ Biolabs Launches Precision Chemical Proteomics Analysis Service
Chemical proteomics analysis service combines synthetic chemistry, cell biology, and mass spectrometry to profile small molecule–protein interactions for target identification, mechanism studies, and off-target evaluation. MtoZ Biolabs provides a one-stop chemical proteomics analysis service featuring Orbitrap MS, advanced probe design, and AI-driven analysis, supporting hit validation, candidate de-risking, and mechanistic research with high resolution and biological relevance. - June 20, 2025 - MtoZ Biolabs
Guided Particle Systems Unveils Vector: A Versatile, Accessible Maskless Photolithography Tool for 2D Electronics Research, Manufacturing, and Workforce Development
Guided Particle Systems, a leader in development of fabrication technologies, materials, and processes to achieve advances in system-level electronic packaging, scaling, and integration, today announced the launch of Vector, a groundbreaking compact maskless photolithography tool designed to... - June 09, 2025 - Guided Particle Systems
Neal Mehta Conducts Research on Controlling Inflammation with Synthetic Peptides
Neal Mehta, a recent biology graduate from Pepperdine University, has made advances in biomedical research. Neal’s work focuses on the use of synthetic peptides to control inflammation, offering a new approach to treating chronic diseases. Mehta, who graduated summa cum laude in May 2025,... - June 03, 2025 - Neal Mehta
Hemanext Welcomes New Member to Board of Directors
Geoff Crouse, an esteemed professional with over 25 years of leadership in the life sciences sector, joins the visionary leadership team guiding Hemanext’s mission to elevate the standard of care for patients who depend on transfusions. - May 21, 2025 - Hemanext
Microvascular Therapeutics: Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)
Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon,... - May 15, 2025 - Microvascular Therapeutics, Inc.
Hemanext Expands Board of Directors with Two New Members
Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, announces the appointment of two distinguished professionals to its Board of Directors. Joe Grogan and Phil Pead join the visionary leaders that are steering Hemanext’s path to improving the standard... - May 05, 2025 - Hemanext